Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH) ( nticoagulantinitially being studied fo...)

HOME >> MEDICINE >> TECHNOLOGY

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul
'"/>

Page: 1 2 3
Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

Post Your Comments:

(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...

(Date:12/14/2009)... Health today announced that executives of the company will ... Goldman Sachs CEO Unplugged Conference on Jan. 6 ... in New York. 28th Annual J.P. Morgan ... at the Westin St. Francis Hotel in San Francisco. ... Cardinal Health,s diverse products and services, company performance and ...

(Date:12/14/2009)... Dec. 14 Southridge LLC ("Southridge"), ... micro-cap companies, is pleased to announce that its affiliated ... up to $15 million in equity financing to Imaging ... the years of financing the growth of Imaging Diagnostic ... continually produce new developments in the field of early ...

Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8 US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9 Cardinal Health Executives to Speak at Two Investor Events in January 2 Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2 Spike Footballs this Fall Without Straining the Spine 54231 1 Spike Footballs this Fall Without Straining the Spine 54231 2 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 1 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 2 Leading Medical Developer Announces Plans for Texoma Medical Plaza 54227 3 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 1 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 2 ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 4846 3

[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Cardinal Health Executives to Speak at Two Investor Events in January [0] Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc.

... SAN DIEGO, Jan. 22 Meritage Pharma, Inc. announced ... clinical trial to evaluate oral viscous budesonide (OVB) for ... (EoE), an allergic inflammatory condition of the esophagus. EoE ... severe cases it can lead to food impaction (food ...

... January 21 PharmaSurgics AB has,received approval from ... phase,I clinical documentation with the novel candidate drug, ... will be initiated in,March 2009. , ... that connect anatomic structures that,should not normally be ...

Other Medicine Technology:Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis 2 Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis 3 Novel Product for Post Surgical Scar Formation Entering Clinical Development 2

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis Novel Product for Post Surgical Scar Formation Entering Clinical Development

(Date:12/15/2009)... -- "The entire San Diego Hospice and The Institute ... Price on December 14, 2009. Mr. Price has been ... ethics in his business, community and personal life. Mr. ... understood the responsibility of philanthropy and the role it ... on through his countless philanthropic efforts. We extend our ...

(Date:12/14/2009)... Unmarried Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, ... Nearly all unmarried young adults ages 18-29 ... of men and 86% of women) and say that ... right now (86% of men and 88% of women), ... to Prevent Teen and Unplanned Pregnancy. Even so: ...

(Date:12/14/2009)... -- Pepsi Bottling Group, ArvinMeritor, Inc., Marathon Oil ... the major employers that implemented Thomson Reuters Informed ... make better decisions about their benefits. ,, The ... of their families, use of healthcare services and ... information, employees can determine which of the available ...

(Date:12/14/2009)... 14 Haemonetics Corporation (NYSE: ... a new legal action to stop Fenwal Inc.,s ... red cell collection kits, using a modified separation ... to circumvent Haemonetics, patent and the injunction entered ... infringing products after December 1, 2010. According ...

(Date:12/14/2009)... Dec. 14 Tough Enough To Wear Pink(TM) ... cancer, celebrated its fifth anniversary at the signature ... Wrangler National Finals Rodeo (Wrangler NFR) in Las ... rough-and-tumble rodeo cowboys, the support of the western ... sold-out crowd sported pink shirts, hats, bracelets and ...

Breaking Medicine News(10 mins):Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3 Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4

[1] San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price [1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference [0] Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process [0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement [0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary

... The Westaim Corporation,announced today that for the first quarter ended ... or 7 cents per share, on revenues of,$5.2 million. In ... of $6.7 million, or 7 cents per share, on revenues ... million for the quarter,compared to $1.9 million in the same ...

... the University of Michigan Comprehensive Cancer Center have found ... more likely to survive cancers of the base of ... found that cancers linked to HPV, or human papillomavirus, ... treatments, while tumors that express high levels of a ...

... Graduate Institute (KGI),today announced that the May 17, 2008, ... in Applied Life Sciences student, Eric,Tan, and the unveiling ... excited and proud of Eric,s achievement in becoming the,first ... Dewey, KGI,s senior,vice president for academic affairs, dean of ...

... VANCOUVER, May 12 /PRNewswire-FirstCall/ - Cardiome Pharma Corp.,(NASDAQ: CRME ... financial,results for the first quarter of 2008 on the ... teleconference call and webcast at 4:30pm,Eastern (1:30pm Pacific) on ... the conference call, please dial 416-641-6117 or,866-299-6655. There will ...

... Slides at 5pm Today, LAWRENCE, Mass., May 12 ... manufacturer of innovative dialysis products,today announced its financial results ... for the first quarter of 2008 were $31.0 million, ... and $29.9 million in the fourth,quarter of 2007. Revenues ...

... - SXC Health Solutions, Corp.,(NASDAQ: SXCI , TSX: ... healthcare IT solutions, announced today that its,2007 Annual Meeting ... 2008 at,5:30 p.m. Eastern Time/4:30 p.m. Central Time at ... The presentation will be webcast live. To access the ...

Westaim announces 2008 first quarter results HPV linked to better survival in tonsil, tongue cancer, U-M study finds KGI 2008 Commencement Features First PhD Graduate, Biotech Painting Cardiome To Release 2008 First Quarter Results NxStage Medical Reports First Quarter 2008 Results SXC Health Solutions to host annual meeting of shareholders May 12, 2008 at 5:30 pm ET/4:30 pm CT

... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...

... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...

... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...

... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...

Medicine Products:

BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q43-CAB-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q66-R-ERB BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q70-CAB-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q73-ERB

( nticoagulantinitially being studied fo...)Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH),Health